TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:02
CASSAVA SCIENCES INC ( SAVA ) https://www.cassavasciences.com
19.76USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-15.77%
SAVA
SPY
32.74%
-57.57%
SAVA
SPY
92.93%
SAVA
1431.78%
SPY
224.41%
-49.59%
SAVA
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
894.58
773.44
0.37
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-9.83
152.32
6.51
-4.68
0.00
-7.02
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
1494611.11
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.2167
-54.78
-61.06
0.79
Other Earnings and Cash Flow Stats:
CASSAVA SCIENCES INC ( SAVA ) Net Income TTM ($MM) is -83.79
CASSAVA SCIENCES INC ( SAVA ) Operating Income TTM ($MM) is -97.06
CASSAVA SCIENCES INC ( SAVA ) Owners' Earnings Annual ($MM) is -55.90
CASSAVA SCIENCES INC ( SAVA ) Current Price to Owners' Earnings ratio is -14.93
CASSAVA SCIENCES INC ( SAVA ) EBITDA TTM ($MM) is -95.71
CASSAVA SCIENCES INC ( SAVA ) EBITDA Margin is 0.00%
Capital Allocation:
CASSAVA SCIENCES INC ( SAVA ) has paid 0.00 dividends per share and bought back -2.034919 million shares in the past 12 months
CASSAVA SCIENCES INC ( SAVA ) has reduced its debt by 0.139 million USD in the last 12 months
Capital Structure:
CASSAVA SCIENCES INC ( SAVA ) Interest-bearing Debt ($MM) as of last quarter is 0
CASSAVA SCIENCES INC ( SAVA ) Annual Working Capital Investments ($MM) are 7
CASSAVA SCIENCES INC ( SAVA ) Book Value ($MM) as of last quarter is 137
CASSAVA SCIENCES INC ( SAVA ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
CASSAVA SCIENCES INC ( SAVA ) has 121 million in cash on hand as of last quarter
CASSAVA SCIENCES INC ( SAVA ) has 14 million of liabilities due within 12 months, and long term debt 0 as of last quarter
CASSAVA SCIENCES INC ( SAVA ) has 42 common shares outstanding as of last quarter
CASSAVA SCIENCES INC ( SAVA ) has 0 million USD of preferred stock value
Academic Scores:
CASSAVA SCIENCES INC ( SAVA ) Altman Z-Score is 32.79 as of last quarter
CASSAVA SCIENCES INC ( SAVA ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
CASSAVA SCIENCES INC ( SAVA ) largest shareholder is owning shares at 0.00 ($MM) value
Sanford Robertson(an insider) Bought 42000 shares of CASSAVA SCIENCES INC ( SAVA ) for the amount of $523320.00 on 2023-08-23
6.04% of CASSAVA SCIENCES INC ( SAVA ) is held by insiders, and 31.37% is held by institutions
CASSAVA SCIENCES INC ( SAVA ) went public on 2000-07-14
Other CASSAVA SCIENCES INC ( SAVA ) financial metrics:
FCF:-57.57
Unlevered Free Cash Flow:-102.37
EPS:-2.43
Operating Margin:1494611.11
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-74.64
Beta:0.79
Buffet's Owners Earnings:-55.90
Price to Owner's Earnings:-14.93
About CASSAVA SCIENCES INC ( SAVA ) :
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.